These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
501 related articles for article (PubMed ID: 1670962)
1. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells. Ganapathi R; Kuo T; Teeter L; Grabowski D; Ford J Mol Pharmacol; 1991 Jan; 39(1):1-8. PubMed ID: 1670962 [TBL] [Abstract][Full Text] [Related]
2. Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells. Kamath N; Grabowski D; Ford J; Drake F; Kerrigan D; Pommier Y; Ganapathi R Cancer Commun; 1991 Feb; 3(2):37-44. PubMed ID: 1995027 [TBL] [Abstract][Full Text] [Related]
3. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells. Ganapathi R; Grabowski D; Rouse W; Riegler F Cancer Res; 1984 Nov; 44(11):5056-61. PubMed ID: 6488165 [TBL] [Abstract][Full Text] [Related]
4. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage. Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973 [TBL] [Abstract][Full Text] [Related]
5. Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases. de la Torre M; Hao XY; Larsson R; Nygren P; Tsuruo T; Mannervik B; Bergh J Anticancer Res; 1993; 13(5A):1425-30. PubMed ID: 7902062 [TBL] [Abstract][Full Text] [Related]
6. Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells. Lack of correlation between cellular doxorubicin levels and expression of resistance. Ganapathi R; Grabowski D Biochem Pharmacol; 1988 Jan; 37(2):185-93. PubMed ID: 3342075 [TBL] [Abstract][Full Text] [Related]
7. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine. Ganapathi R; Grabowski D; Schmidt H Biochem Pharmacol; 1986 Feb; 35(4):673-8. PubMed ID: 3947398 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Slovak ML; Hoeltge GA; Dalton WS; Trent JM Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069 [TBL] [Abstract][Full Text] [Related]
9. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833 [TBL] [Abstract][Full Text] [Related]
10. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity. Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233 [TBL] [Abstract][Full Text] [Related]
11. Selective enhancement of vincristine cytotoxicity in multidrug-resistant tumor cells by dilantin (phenytoin). Ganapathi R; Hercbergs A; Grabowski D; Ford J Cancer Res; 1993 Jul; 53(14):3262-5. PubMed ID: 8100737 [TBL] [Abstract][Full Text] [Related]
12. Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance. Ganapathi R; Schmidt H; Grabowski D; Melia M; Ratliff N Br J Cancer; 1988 Sep; 58(3):335-40. PubMed ID: 3179186 [TBL] [Abstract][Full Text] [Related]
13. Time dependence of [3H]-vincristine accumulation by L1210 mouse leukemic cells. Effect of P-glycoprotein overexpression. Breier A; Stefanková Z; Barancík M; Tribulová N Gen Physiol Biophys; 1994 Aug; 13(4):287-98. PubMed ID: 7890145 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells. Slapak CA; Fracasso PM; Martell RL; Toppmeyer DL; Lecerf JM; Levy SB Cancer Res; 1994 Nov; 54(21):5607-13. PubMed ID: 7923205 [TBL] [Abstract][Full Text] [Related]
15. Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype. Kamath N; Grabowski D; Ford J; Ganapathi R Br J Cancer; 1993 Jun; 67(6):1203-8. PubMed ID: 8099806 [TBL] [Abstract][Full Text] [Related]
16. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein. Haber M; Norris MD; Kavallaris M; Bell DR; Davey RA; White L; Stewart BW Cancer Res; 1989 Oct; 49(19):5281-7. PubMed ID: 2569932 [TBL] [Abstract][Full Text] [Related]
17. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance. Politi PM; Sinha BK Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628 [TBL] [Abstract][Full Text] [Related]
18. Bcl-2 and mdr-1 gene expression during doxorubicin-induced apoptosis in murine leukemic P388 and P388/R84 cells. Ramachandran C; You W; Krishan A Anticancer Res; 1997; 17(5A):3369-76. PubMed ID: 9413174 [TBL] [Abstract][Full Text] [Related]
19. Direct interaction between verapamil and doxorubicin causes the lack of reversal effect of verapamil on P-glycoprotein mediated resistance to doxorubicin in vitro using L1210/VCR cells. Breier A; Drobná Z; Barancík M Neoplasma; 1998; 45(4):248-53. PubMed ID: 9890669 [TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance. Ogretmen B; McCauley MD; Safa AR Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]